3Paes FM,Kalkanis DG,Sideras PA,et al.FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease[J].Radiographics,2010,30(1):269-291.
4Otero HJ,Jagannathan JP,Prevedello LM,et al.CT and PET/CT findings of T-cell lymphoma[J].AIR Am J Roentgenol,2009,193(2):349-358.
5Solal-Celiqny P,Roy P,Colombat P,et al.Follicu-lar lymphoma international prognosis index[J].Blood,2004,104(5):1258-1265.
6Thomas DW,Owen RG,Johnson SA,et al.Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophos-phamide with or without rituximab compared with prior responses to CHOP.[J].Leuk Lymphoma,2005,46(4):549-552.
7Habermann TM,Weller EA,Morrison VA,et al.Ritux-imab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma[J].J Clin Oncol,2006,24(19):3121-3127.
8Michallet AS,Coiffier B.Recent developments in the treatment of aggressive non-Hodgkin lymphoma[J].Blood Rev,2009,23(l):11-23.
9Jovanovic MP,Jakovic L,Bogdanovic A,et al.Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells[J].Vojnosanit Pregl,2009,66(9):738-743.
10Andersen NS,Jensen MK,de Nully Brown P,et al.A Danish population-based analysis of 105 mantle cell lymphoma patients:incidences,clinical features,re-sponse,survival and prognostic factors[J].Eur J Cancer,2002,38(3):401 -408.
7HARTGE P,DEVESA S S.Quantification of the impact of known risk factors on time trends in nonHodgkin's lymphoma incidence[J].Cancer Res (Suppl),1992,52:5566S-5569S.
8BALLESTER O F,MOSCINSKY L,SPIERS M,et al.Non-Hodgkin's lymphoma in the older person:A review[J].J Am Geriatr Soc,1993,41:245-646.
9SHIPP M,HARRINGTON D,ANDERSON J,et al.A predictive model for aggressive non-Hodgkin's lymphoma.The international Non-Hodgkin's Lymphoma Prognostic Factors Project[J].N Engl J Med,1993,329:987-994.
10ARMITAGE J O,WEISENBURGER D D.New approach to classfying non-Hodgkin's lymphomas:clinical features of the major histologic subtypes.NonHodgkin's Lymphoma Classfication Project[]].J Clin Oncol,1998,16:2780-2795.
6Hartge P,Devesa SS. Quantification of the impact of known risk factors on time trends in non Hodgkin's lymphoma incidence[J]. Cancer Res (Suppl), 2006,52 : 5566s-5569s.
7Schrier R W, Wang W,Poole B,et al. Acute renal failure :defini- tions, diagnosis,pathogenesis,and therapy [J]. J Clin Invest,2007, 114(1):5-7.
8Norbert L,Vim Van B ,et al. Acute renal problems in the critically ill cancer patient [J]. Current Opinion in critical Care,2008,14: 635-646.
9Olioso P,Giancola R,Di Riti M,et al.Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours:a pilot clinical trial[J].Hematol Oncol,2009,27 (3):130-139.
10Sheu BC,Hsu SM,Ho HN,et al.Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma[J]Cancer,1999,86 (8):1537-1543.
